2 Biotech Stock to Buy Over Moderna This December Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth,… Previous Article Is Carvana Stock a Buy at $5 per Share? Next Article Bring Your Remote Employees into the Holiday Party With This Alcohol Delivery Service
